Scarica l'app Stockscreener
67.39
1.13%
0.75
Pre-mercato:
67.40
0.01
+0.01%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BBIO Giù?
Forum
Previsione
Precedente Chiudi:
$66.64
Aprire:
$66.67
Volume 24 ore:
1.60M
Relative Volume:
0.65
Capitalizzazione di mercato:
$13.20B
Reddito:
$579.96M
Utile/perdita netta:
$-729.89M
Rapporto P/E:
-17.99
EPS:
-3.7459
Flusso di cassa netto:
$-452.02M
1 W Prestazione:
-0.02%
1M Prestazione:
+1.91%
6M Prestazione:
-8.96%
1 anno Prestazione:
+68.18%
Intervallo 1D:
$66.30
$68.61
Intervallo di 1 settimana:
$65.83
$69.03
Portata 52W:
$39.65
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Nome
Bridgebio Pharma Inc
Settore
Industria
Telefono
(650) 391-9740
Indirizzo
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
67.39 | 13.32B | 579.96M | -729.89M | -452.02M | -3.7459 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-09 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-03-10 | Iniziato | William Blair | Outperform |
| 2026-01-28 | Iniziato | Barclays | Overweight |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-11 | Iniziato | Bernstein | Outperform |
| 2025-07-30 | Ripresa | Raymond James | Outperform |
| 2025-07-21 | Iniziato | Truist | Buy |
| 2025-07-14 | Iniziato | Jefferies | Buy |
| 2025-07-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Iniziato | Wolfe Research | Outperform |
| 2025-03-31 | Iniziato | Redburn Atlantic | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-10-03 | Iniziato | Oppenheimer | Perform |
| 2024-09-04 | Iniziato | Piper Sandler | Overweight |
| 2024-03-21 | Ripresa | Raymond James | Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Market Perform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-11-07 | Iniziato | Citigroup | Buy |
| 2023-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Downgrade | Jefferies | Buy → Hold |
| 2023-04-19 | Iniziato | Evercore ISI | Outperform |
| 2023-02-06 | Iniziato | Cowen | Outperform |
| 2021-12-27 | Reiterato | Mizuho | Buy |
| 2021-12-27 | Reiterato | SVB Leerink | Outperform |
| 2021-09-10 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-03-22 | Reiterato | Goldman | Buy |
| 2021-02-22 | Ripresa | JP Morgan | Overweight |
| 2021-02-09 | Ripresa | Goldman | Buy |
| 2021-01-11 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-10 | Reiterato | H.C. Wainwright | Buy |
| 2020-06-25 | Iniziato | BofA/Merrill | Neutral |
| 2020-05-19 | Iniziato | BTIG Research | Buy |
| 2020-04-13 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-19 | Iniziato | Mizuho | Buy |
| 2019-07-26 | Iniziato | Raymond James | Outperform |
| 2019-07-22 | Iniziato | BMO Capital Markets | Outperform |
| 2019-07-22 | Iniziato | Goldman | Buy |
| 2019-07-22 | Iniziato | JP Morgan | Overweight |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-07-22 | Iniziato | Piper Jaffray | Overweight |
| 2019-07-22 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Bridgebio Pharma Inc Borsa (BBIO) Ultime notizie
Mizuho Cuts Price Target on BridgeBio Pharma to $96 From $106, Keeps Outperform Rating - marketscreener.com
BBIO (NASDAQ) Form 144 shows proposed sale of 83,088 shares and RSUs - Stock Titan
Mizuho Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Cuts Target Price to $96 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring A Potential 53.76% Upside - DirectorsTalk Interviews
The Technical Signals Behind (BBIO) That Institutions Follow - Stock Traders Daily
Monashee Investment Management LLC Sells 100,000 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BofA Securities Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $101 - Moomoo
Dksh Management Ltd. Enters Distribution Partnership with Bridgebio Pharma, Inc. to Support Regulatory Evaluation and Potential Patient Access to Transthyretin Stabilizer for Attr-Cm in Australia, Singapore, South Korea, and Taiwan - marketscreener.com
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) - MarketBeat
BridgeBio Pharma, Inc. $BBIO Shares Acquired by GW&K Investment Management LLC - MarketBeat
BridgeBio Pharma, Inc. $BBIO Position Lifted by Franklin Resources Inc. - MarketBeat
Axiom Investors LLC DE Has $15.87 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Raymond James downgrades BridgeBio Pharma (BBIO) - MSN
TD Asset Management Inc Boosts Stake in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Insider Sold Shares Worth $5,413,289, According to a Recent SEC Filing - marketscreener.com
BridgeBio Pharma CEO Neil Kumar sells $5.4m in company stock By Investing.com - Investing.com South Africa
BridgeBio Pharma CEO Neil Kumar sells $5.4m in company stock - Investing.com Australia
BridgeBio Pharma(BBIO.US) Officer Sells US$5.41 Million in Common Stock - Moomoo
BridgeBio Pharma (BBIO) CEO’s family trusts sell 80,000 shares under 10b5-1 plan - Stock Titan
Mizuho reiterates Outperform on BridgeBio stock on Russell move By Investing.com - Investing.com Canada
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Uncovering a Potential 51.92% Upside in the Biotechnology Sector - DirectorsTalk Interviews
Operating income of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Return on assets % of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Quick ratio of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
Gross profit of BridgeBio Pharma, Inc. – XETR:2CL - TradingView
ETFs Investing in BridgeBio Pharma, Inc. Stocks - TradingView
BridgeBio Pharma, Inc. Balance Sheet – XETR:2CL - TradingView
BridgeBio Pharma, Inc. Cash Flow – XETR:2CL - TradingView
Biotech BridgeBio hands new recruits 31,428 stock units - Stock Titan
Brazil approves BridgeBio’s acoramidis for heart condition - Investing.com
Barclays Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $157 - Moomoo
BBIO: Attruby’s rapid growth and differentiated data anchor a pipeline poised for multiple rare disease launches - TradingView
BBIO: Attruby's rapid growth and differentiated data drive momentum as multiple rare disease launches near - TradingView
symbol__ Stock Quote Price and Forecast - CNN
BridgeBio (BBIO) Receives Buy Rating with $104 Target by Canacco - GuruFocus
CCORF Initiates BridgeBio Pharma(BBIO.US) With Buy Rating, Announces Target Price $104 - Moomoo
Canaccord Genuity Group Initiates Coverage on BridgeBio Pharma (NASDAQ:BBIO) - MarketBeat
Precision Trading with Bridgebio Pharma Inc. (BBIO) Risk Zones - Stock Traders Daily
BridgeBio Pharma director Ellis Andrea sells $4.2m in shares - Investing.com
Geode Capital Management LLC Purchases 502,582 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Citi Maintains BridgeBio Pharma(BBIO.US) With Hold Rating, Maintains Target Price $82 - Moomoo
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Promising 54.93% Upside Potential - DirectorsTalk Interviews
Does FDA Priority Review for First LGMD Therapy Change The Bull Case For BridgeBio Pharma (BBIO)? - Yahoo Finance
BridgeBio gains as muscular dystrophy therapy gets FDA priority review - MSN
Farallon funds hold multi‑million share positions in BridgeBio (NASDAQ: BBIO) - Stock Titan
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98. - GuruFocus
BBIO Maintained by Morgan Stanley -- Price Target Raised to $98.00 - GuruFocus
H.C. Wainwright Maintains BridgeBio Pharma(BBIO.US) With Buy Rating, Maintains Target Price $110 - Moomoo
BBIO Reiterates by HC Wainwright & Co. -- Price Target Maintained at $110 - GuruFocus
FDA accepts BridgeBio’s BBP-418 for priority review - The Pharma Letter
Analysts Offer Insights on Healthcare Companies: BridgeBio Pharma (BBIO) and Cocrystal Pharma (COCP) - The Globe and Mail
Bridgebio Pharma Inc Azioni (BBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Bridgebio Pharma Inc Azioni (BBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Jun 05 '26 |
Sale |
67.88 |
40,000 |
2,715,077 |
515,686 |
| Kumar Neil | Chief Executive Officer |
Jun 04 '26 |
Sale |
67.46 |
40,000 |
2,698,211 |
535,686 |
| Kumar Neil | Chief Executive Officer |
May 21 '26 |
Sale |
69.44 |
26,103 |
1,812,522 |
243,327 |
2.60%
0.94%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):